577 marketing authorisations granted (356 active ingredients) by EU centralized procedure, 1995-2009 522 marketing authorisations granted (339 active ingredients)

Slides:

Advertisements

Similar presentations

Recipe for ??????????????????????????????? What you will make Ingredients What to do

Advertisements

April 2010 – An Opportunity for the Herbal Industry Jonathan Griffith.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

An Update on the Crisis George Z. Georgiou – George Z. Georgiou & Associates LLC September 2013.

The Paediatric Regulation

Trademarks as a Business Asset and the Power of Branding Heinz Goddar / Ludwig Kouker April 26/28, /28HG-3 26/28/04/2014 – Trademarks in.

Reference, Retention and Reserve Samples

ANSI ISO ICCA Program. ISO Standards ISO sets an internationally recognized benchmark to assure that the certification organization meets the set.

API Inspections: the EDQM experience 29 March 2010

Facts and Figures 2008 Medicines and Health Care The Norwegian Association of Pharmaceutical Manufacturers (LMI)

THE UK EXPERIENCE RELATED TO ESCITALOPRAM seeking clarity in the EU interest IS THE UK’S REFERRAL TO CHMP UNDER ARTICLE 31 OF DIRECTIVE 2001/83 LEGITIMATE?

Summary About me & AMRC About the EU Clinical Trials Regulation – what’s new Implementation timeline What does this mean for UK ethicists?

Central Office for Research Ethics Committees (COREC) New system for Research Ethics Committees Sure Start – April 2004 Joan Kirkbride OREC Manager for.

Dr Peter Arlett European Commission Orphan medicines: DG Enterprise and Industry perspective ICORD February 2005.

The Pharmaceutical Industry in Turkey

EuropeAid 1 Delegation Agreements: 2011 templates “Regards Croisés” on Aid Effectiveness Practitioners’ Network for European Development Cooperation -

EU Council Directive on Traditional Herbal Medicinal Products Dr. Dairine Dempsey IRISH MEDICINES BOARD for IHTA AGM 23 rd April 2003.

1 Regulation (EC) No 1924/2006 on Nutrition and Health Claims by Basil Mathioudakis European Commission Head of Unit Food Law, Nutrition and Labelling.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. European.

Marcel H.N. Hoefnagel 2 November 2007 BIOSIMILARS are not Generics But similar.

Review of veterinary medicines legislation in 2010 Mario Nagtzaam Unit F2 „Pharmaceuticals“ Directorate-General Enterprise and Industry European Commission.

Gaining Regulatory Approval Establishing and Meeting regulatory Requirements ICORD 2006 Madrid, 25 October 2006 Channa Debruyne, MD The European Medicines.

Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.

Browse more reports on Pharmaceuticals at sciences/pharmaceuticals.

ESSEX AGRICULTURAL AND TECHNICAL HIGH SCHOOL Professional Development Copyright, Plagiarism and Cheating Presented by: Debra A. Murphy, M.A., M.L.I.S.

Renewable Energy: DTI’s Role John Thorpe Renewable Energy Industry Development Eastern Region Renewable Energy Conference, 5 June 2003.

International conference Quality of Active Pharmaceutical Ingredients Hyderabad, September 2009 API Inspections: the EDQM experience – 7 September.

Federal agency for medicines and health products VARIATIONS AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne Mouyart – Belgium, Unit Homeo-Phyto HMPWG Gdańsk.

1 10/15/04CS150 Introduction to Computer Science 1 Reading from and Writing to Files Part 2.

1. 2 > ˜100 3 >2 000 > Paediatric regulation.

Process mapping of registration to reimbursement for new pharmaceuticals in UK.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)

IMPLEMENTING MEASURES GM FOOD – FEED REGULATION (EC) N° 1829/2003 -Articles 5 and 17 concerning the presentation and preparation of the application -Articles.

Emergency Stopping Signal 80th GRRF session Submitted by the experts from IMMA Informal document GRRF th GRRF, September 2015, Agenda item.

Supplementary Protection Certificates – Some Unresolved Issues Trevor Cook 28 September 2015.

Date Insert on Master Slide Slide 1 Regulatory Framework within which patients can have safe and more convenient access to medicines Royal College of Physicians.

* Remark: Final Energy Demand Including Renewable Energy *

REGULATION (EC) Nº 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products 1 Shall apply from 11.

Financing Community Organisations. CONTEXT THE STRATEGIC DEVELOPMENT PLAN.

Quality of the medicinal products. Drug switching.

US Burden of Disease and Injury Study, 1996

Template for country interventions (5 min)

Herbal Medicines.

Supporting SME Eléonore Cornu M2 Areips Supporting SMEs.

Sophie Skorupka M2 AREIPS 15 novembre 2016

REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.

European case studies relating to the administrative approach

eSubmission Web Client – XML delivery files

Union referral procedures

Median 25th and 75th percentile

African Regional Meeting on 4-5 July 2017 in Entebbe, Uganda

eSubmission Web Client XML delivery file – new functionality

Close-out Procedures 90 Days

EURIPIDES² Prague Forum June 2014

New active substances approved by EMA and FDA over 10 years

EMA: The European Medicines Agency

CONGRESS Women’s Conference Building Equality into Recovery

State of play in the EU for criteria to identify endocrine disruptors

Jane Lenehan, Scientific Animal Protection Manager (acting)

Presentation to the Health Portfolio Committee

New drug development The Lancet Volume 377, Issue 9769, (March 2011)

Prescription-only vs. over-the-counter medicines

GMOs Legislation in EU.

1. Why Marketing Research?

Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010 Note: EMA approval.

GL8 (R) – Stability testing for medicated premixes

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Distribution of product medicinal products without commercial interest (MPWCI) presentations (original list) studied due to the age of the marketing authorisation.

Presentation transcript:

577 marketing authorisations granted (356 active ingredients) by EU centralized procedure, 1995-2009 522 marketing authorisations granted (339 active ingredients) selected for the analysis 55 marketing authorisations withdrawn, suspended and/or not renewed (45 active ingredients) excluded from the analysis 2 marketing authorisations granted to medicinal products with no specific indication (1 active ingredient) excluded 520 marketing authorisations granted (338 active ingredients) finally included in the analysis with disease burden measures